{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T18:02:41Z","timestamp":1781805761147,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd012433","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000}}],"reference-count":75,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012433.pub2","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T12:28:41Z","timestamp":1583324921000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Oxcarbazepine add-on for drug-resistant focal epilepsy"],"prefix":"10.1002","volume":"2020","author":[{"given":"Rebecca","family":"Bresnahan","sequence":"first","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Lower Lane Liverpool UK L9 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Atim-Oluk","sequence":"additional","affiliation":[{"name":"South Wales Deanery; Swansea UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Lower Lane Liverpool UK L9 7LJ"},{"name":"The Walton Centre NHS Foundation Trust; Liverpool UK"},{"name":"Liverpool Health Partners; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD012433.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD012433.pub2-BIB0002|cit2","first-page":"307","article-title":"Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs","volume":"45","author":"D'Souza","year":"2004","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0003|cit3","first-page":"97","article-title":"Safety and efficacy of oxcarbazepine in refractory epilepsy","volume":"41 Suppl Floren","author":"Walker","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0004|cit4","unstructured":"EUCTR2008-003333-25-BG PROSPER www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-003333-25\/BG"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"French JA Baroldi P Brittain ST Johnson JK Abou-Khalil B Brower R Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR\u2122) as adjunctive therapy in patients with refractory partial-onset seizures: A randomized controlled trial. Acta Neurologica Scandinavica 2014 143 53","DOI":"10.1111\/ane.12207"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012433.pub2-BIB0006|cit6","first-page":"224, Abstract n","article-title":"Efficacy and tolerability of spn-804, a novel, once-daily, extended-release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation","volume":"12","author":"Horich","year":"2012","journal-title":"Epilepsy Currents \/ American Epilepsy Society"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Johnson J Brittain S Louro D Efficacy and tolerability of SPN-804, a novel, once-daily, extended-release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation Neurology 2013 P02.213","DOI":"10.1212\/WNL.80.7_supplement.P02.213"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0008|cit8","unstructured":"NCT00772603 Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) clinicaltrials.gov\/ct2\/show\/NCT00772603"},{"issue":"12","key":"10.1002\/14651858.CD012433.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1212\/WNL.54.12.2237","article-title":"Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group","volume":"54","author":"Glauser","year":"2000","journal-title":"Neurology"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD012433.pub2-BIB0010|cit10","first-page":"57","article-title":"Two-year long-term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]","volume":"43","author":"Glauser","year":"2002","journal-title":"Epilepsia"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD012433.pub2-BIB0011|cit11","first-page":"266","article-title":"Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure-free rates","volume":"44","author":"Glauser","year":"2003","journal-title":"Epilepsia"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD012433.pub2-BIB0012|cit12","first-page":"183","article-title":"Two year long-term safety and efficacy of oxcarbazepine (Trileptal\u00c2\u00ae) in children with refractory partial epilepsy","volume":"43","author":"Glauser","year":"2002","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD012433.pub2-BIB0013|cit13","first-page":"64","article-title":"Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy","volume":"43","author":"Sachdeo","year":"2002","journal-title":"Epilepsia"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD012433.pub2-BIB0014|cit14","first-page":"183","article-title":"Oxcarbazepine (Trileptal\u00c2\u00ae) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy","volume":"43","author":"Sachdeo","year":"2002","journal-title":"Epilepsia"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD012433.pub2-BIB0015|cit15","first-page":"S119","article-title":"Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs","volume":"52","author":"Sachdeo","year":"2002","journal-title":"Annals of Neurology"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD012433.pub2-BIB0016|cit16","first-page":"146","article-title":"Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures","volume":"45","author":"Wilfong","year":"2004","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012433.pub2-BIB0017|cit17","first-page":"S193","article-title":"Oxcarbazepine as add-on therapy in Thai epileptic patients with refractory partial seizures","volume":"88","author":"Kraiprab","year":"2005","journal-title":"Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0018|cit18","unstructured":"NCT00975715 Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures ClinicalTrials.gov\/show\/NCT00975715"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0019|cit19","unstructured":"NCT00050934 Pediatric Epilepsy Study clinicaltrials.gov\/ct2\/show\/NCT00050934"},{"issue":"9","key":"10.1002\/14651858.CD012433.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1212\/01.wnl.0000186800.18456.72","article-title":"Oxcarbazepine adjunctive therapy in infants and young children with partial seizures","volume":"65","author":"Pina-Garza","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0021|cit21","unstructured":"EUCTR2004-002260-25-AT OXC retard https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002260-25\/AT"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0022|cit22","unstructured":"EUCTR2006-003834-14-DE EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-003834-14\/DE"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0023|cit23","unstructured":"EUCTR2008-003334-19-BG Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-003334-19\/BG"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD012433.pub2-BIB0024|cit24","first-page":"54","article-title":"Long-term efficacy and safety of adjunctive oxcarbazepine therapy in children with partial-onset seizures [abstract]","volume":"42","author":"Glauser","year":"2001","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD012433.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1528-1157.1987.tb03702.x","article-title":"Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?","volume":"28","author":"Houtkooper","year":"1987","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD012433.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1525-5050(03)00037-4","article-title":"Safety and tolerability of oxcarbazepine in elderly patients with epilepsy","volume":"4","author":"Kutluay","year":"2003","journal-title":"Epilepsy & Behavior"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012433.pub2-BIB0027|cit27","first-page":"122","article-title":"Oxcarbazepine and cognitive function after a single dose and during a double-blind placebo-controlled cross-over study","volume":"34","author":"Gillham","year":"1993","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD012433.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.1994.tb04234.x","article-title":"A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients","volume":"37","author":"McKee","year":"1994","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0029|cit29","unstructured":"NCT00050947 Pediatric Epilepsy Study clinicaltrials.gov\/ct2\/show\/NCT00050947"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0030|cit30","unstructured":"NCT00391534 EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy clinicaltrials.gov\/ct2\/show\/NCT00391534"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0031|cit31","unstructured":"NCT00918424 Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects clinicaltrials.gov\/ct2\/show\/NCT00918424"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0032|cit32","unstructured":"NCT01891890 Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE) (COPE) clinicaltrials.gov\/ct2\/show\/NCT01891890"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012433.pub2-BIB0033|cit33","first-page":"S104","article-title":"Multicenter study of oxcarbazepine pharmacokinetics and tolerability in children with refractory epilepsy","volume":"50","author":"Dulac","year":"2001","journal-title":"Annals of Neurology"},{"issue":"11","key":"10.1002\/14651858.CD012433.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1177\/0091270004266617","article-title":"Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy","volume":"44","author":"Rey","year":"2004","journal-title":"Journal of Clinical Pharmacology"},{"issue":"10","key":"10.1002\/14651858.CD012433.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00115-012-3598-2","article-title":"[Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study]","volume":"83","author":"Steinhoff","year":"2012","journal-title":"Der Nervenarzt"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0036|cit36","unstructured":"CTRI\/2010\/091\/000100 A Clinical Trial to Investigate Efficacy and Safety of Eslicarbazepine Acetate Tablet versus Oxcarbazepine SR Tablet Eslicarbazepine as an Adjunctive Treatment in Patients With Refractory Epilepsy Suffering From Partial Onset Seizures With or Without Secondary Generalisation www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=1315"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0037|cit37","unstructured":"CTRI\/2010\/091\/001194 Clinical Study to evaluate efficacy and safety of Eslicarbazepine acetate as an adjunctive therapy in partial-onset seizures www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=1992"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0038|cit38","unstructured":"CTRI\/2010\/091\/006085 13-week study for evaluation of efficacy and safety of in-aqul-002 tablet compared to oxcarbazepine sustained-release tablet as adjunctive treatment in adult patients with refractory partial-onset seizures www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=2479"},{"issue":"8","key":"10.1002\/14651858.CD012433.pub2-BIB0039|cit39","first-page":"370","article-title":"[Oxcarbazepine]","volume":"16","author":"Arroyo","year":"2001","journal-title":"Neurologia"},{"issue":"1","key":"10.1002\/14651858.CD012433.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00023210-200418010-00006","article-title":"Spotlight on oxcarbazepine in epilepsy","volume":"18","author":"Bang","year":"2003","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1002\/14651858.CD012433.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/epi.12605","article-title":"An unknown quantity - the worldwide prevalence of epilepsy","volume":"55","author":"Bell","year":"2014","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD012433.pub2-BIB0042|cit42","first-page":"69","article-title":"Clinical experience with oxcarbazepine","volume":"20","author":"Beydoun","year":"2002","journal-title":"Today's Therapeutic Trends"},{"issue":"3","key":"10.1002\/14651858.CD012433.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.seizure.2011.10.011","article-title":"Co-morbidity of epilepsy in Tanzanian children: a community-based case-control study","volume":"21","author":"Burton","year":"2012","journal-title":"Seizure"},{"issue":"10","key":"10.1002\/14651858.CD012433.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1528-1157.1998.tb01295.x","article-title":"Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards","volume":"39","author":"Cochrane","year":"1998","journal-title":"Epilepsia"},{"issue":"8968","key":"10.1002\/14651858.CD012433.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the National General Practice Study of Epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012433.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD012433.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","article-title":"Overview of the clinical pharmacokinetics of oxcarbazepine","volume":"24","author":"Flesch","year":"2004","journal-title":"Clinical Drug Investigation"},{"issue":"3","key":"10.1002\/14651858.CD012433.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"ILAE Subcommission on AED Guidelines: updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0049|cit49","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro Guideline Development Tool 2015"},{"issue":"6","key":"10.1002\/14651858.CD012433.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00003495-199243060-00007","article-title":"Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders","volume":"43","author":"Grant","year":"1992","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0051|cit51","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD012433.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.33588\/rn.4202.2005576","article-title":"Oxcarbazepine in the treatment of epilepsy. A review and update","volume":"42","author":"Horga de la Parte","year":"2006","journal-title":"Revista de Neurologia"},{"issue":"4","key":"10.1002\/14651858.CD012433.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the International League Against Epilepsy","volume":"30","author":"Anonymous","year":"1989","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD012433.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2009","journal-title":"Epilepsia"},{"issue":"5","key":"10.1002\/14651858.CD012433.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"680-700; discus","DOI":"10.1016\/S0149-2918(01)80019-9","article-title":"Oxcarbazepine, an antiepileptic agent","volume":"23","author":"Kalis","year":"2001","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD012433.pub2-BIB0056|cit56","first-page":"646","article-title":"A follow up study on newer anti-epileptic drugs as add-on and monotherapy for partial epilepsy in China","volume":"125","author":"Kang","year":"2012","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD012433.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-2007-1017521","article-title":"Oxcarbazepine (Trileptal\u00ae): A new antiepileptic drug for mono- and add-on- therapy","volume":"27","author":"Kr\u00e4mer","year":"2000","journal-title":"Aktuelle Neurologie"},{"issue":"5","key":"10.1002\/14651858.CD012433.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0074-7742(08)00020-2","article-title":"Chapter 20: psychiatric comorbidities in epilepsy","volume":"83","author":"LaFrance","year":"2008","journal-title":"International Review of Neurobiology"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0061|cit61","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"8","key":"10.1002\/14651858.CD012433.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD012433.pub2-BIB0063|cit63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002896.pub2","article-title":"Vagus nerve stimulation for partial seizures","author":"Panebianco","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0064|cit64","first-page":"409","article-title":"Chapter 24 - Antiseizure Drugs","volume-title":"Basic and Clinical Pharmacology","author":"Porter","year":"2018"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012433.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1111\/j.1528-1157.1999.tb00919.x","article-title":"Evidence-based medicine and antiepileptic drugs","volume":"40","author":"Privitera","year":"1999","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0066|cit66","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"3","key":"10.1002\/14651858.CD012433.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1590\/S1516-31802009000300008","article-title":"Oxcarbazepine for refractory epilepsy: systematic review of the literature","volume":"127","author":"Saconato","year":"2009","journal-title":"Sao Paulo Medical Journal"},{"issue":"8726","key":"10.1002\/14651858.CD012433.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/0140-6736(90)92959-L","article-title":"National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population","volume":"336","author":"Sander","year":"1990","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012433.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0070|cit70","unstructured":"Sch\u00fcnemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012433.pub2-BIB0071|cit71","volume-title":"Handbook of Epilepsy Treatment","author":"Shorvon","year":"2013"},{"issue":"2","key":"10.1002\/14651858.CD012433.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/seiz.2001.0536","article-title":"Clinical recommendations for oxcarbazepine","volume":"10","author":"Smith","year":"2001","journal-title":"Seizure"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD012433.pub2-BIB0073|cit73","first-page":"123","article-title":"Long-term efficacy and safety of oxcarbazepine (Trileptal\u00ae) combination therapy in patients with refractory partial seizures","volume":"43","author":"Walker","year":"2002","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD012433.pub2-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010541.pub3","article-title":"Surgery for epilepsy","author":"West","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD012433.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012433","article-title":"Oxcarbazepine add-on for drug-resistant partial epilepsy","author":"Atim-Oluk","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T15:41:11Z","timestamp":1722526871000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012433.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":75,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012433.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]}}}